echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Half-year medical commercial bribery cases will be notified and included in the credit rating of pharmaceutical companies

    Half-year medical commercial bribery cases will be notified and included in the credit rating of pharmaceutical companies

    • Last Update: 2021-06-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 26, the National Health Commission announced the recent work of ensuring supply and price stabilization of shortages of medicines, which mentioned an important piece of information that is closely related to pharmaceutical companies.

    Before we talk about the main text, let’s review one thing.


    You should remember that Dami has emphasized in relevant information since the end of last year.


    Later, I shared with you in January this year.


    Since January this year, the National Medical Insurance Administration has established a dispatch mechanism and started to track the progress of this work and the handling of typical cases in various recruitment agencies.


    In addition, the "Pharmaceutical Enterprise Price and Marketing Behavior Credit Commitment", which has been prepared by the National Medical Insurance Administration since 2019, has been implemented in the drug price and recruitment credit evaluation system at the beginning of this year.


    Announcements.


    The specific requirements are as follows: For those who have not submitted a written commitment, from April 1, 2021, the provincial centralized procurement agencies will no longer accept their new bids or online applications; since June 1, they have won the bid If there are other companies to guarantee the supply of pharmaceutical products or have alternatives to meet clinical needs, they should be removed from the network.

    In the public announcement of the Health Commission on the 26th, it was mentioned that supervision and law enforcement should be further strengthened, and various illegal drug operations should be severely investigated and dealt with, including the comprehensive implementation of the establishment of a medical price and recruitment credit evaluation system, under the guidance of the National Medical Insurance Administration.


    All localities have established a credit evaluation system, published a list of untrustworthy items, organized enterprises to submit credit commitments, notified information on medical and commercial bribery cases judged by the court in the third and fourth quarters of 2020, and required relevant provinces to include credit ratings after verification and adopt restrictive measures.


    The "Guiding Opinions on Establishing a Pharmaceutical Price and Recruitment Credit Evaluation System" was officially released by the National Medical Insurance Bureau on September 16 last year.


    One of its main goals is to build pharmaceutical companies in stages to "dare, can't, and don't want" to give rebates.


    On May 26, the National Health Commission announced the recent work of ensuring supply and price stabilization of shortages of medicines, which mentioned an important piece of information that is closely related to pharmaceutical companies.

    Before we talk about the main text, let’s review one thing.


    You should remember that Dami has emphasized in relevant information since the end of last year.


    Later, I shared with you in January this year.


    Since January this year, the National Medical Insurance Administration has established a dispatch mechanism and started to track the progress of this work and the handling of typical cases in various recruitment agencies.


    In addition, the "Pharmaceutical Enterprise Price and Marketing Behavior Credit Commitment", which has been prepared by the National Medical Insurance Administration since 2019, has been implemented in the drug price and recruitment credit evaluation system at the beginning of this year.


    Announcements.


    The specific requirements are as follows: For those who have not submitted a written commitment, from April 1, 2021, the provincial centralized procurement agencies will no longer accept their new bids or online applications; since June 1, they have won the bid If there are other companies to guarantee the supply of pharmaceutical products or have alternatives to meet clinical needs, they should be removed from the network.

    In the public announcement of the Health Commission on the 26th, it was mentioned that supervision and law enforcement should be further strengthened, and various illegal drug operations should be severely investigated and dealt with, including the comprehensive implementation of the establishment of a medical price and recruitment credit evaluation system, under the guidance of the National Medical Insurance Administration.
    All localities have established a credit evaluation system, published a list of untrustworthy items, organized enterprises to submit credit commitments, notified information on medical and commercial bribery cases judged by the court in the third and fourth quarters of 2020, and required relevant provinces to include credit ratings after verification and adopt restrictive measures.

    The "Guiding Opinions on Establishing a Pharmaceutical Price and Recruitment Credit Evaluation System" was officially released by the National Medical Insurance Bureau on September 16 last year.
    One of its main goals is to build pharmaceutical companies in stages to "dare, can't, and don't want" to give rebates.
    Governance system.
    As you can see, in the past year or so, in addition to the introduction of the National Medical Insurance Bureau and other institutions, relevant state agencies have also dealt with individual enterprises and made reports.
    Currently, the courts in the second half of 2020 The notification and handling of the judged medical and commercial bribery case information also shows that mid-2020 is a key node.
    For some large enterprises, do not use the ship to turn around as an excuse, otherwise they may face a lot of credit evaluation.
    Corporate crisis.
    (Medicine Representative)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.